Blueprint Medicines Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Blueprint Medicines (BPMC) Tops Q1 EPS by 13c
May 10, 2016 8:45 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.57), $0.13 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $6.86 million versus the consensus estimate of $3.24 million.
Blueprint Medicines expects that its cash, cash equivalents and investments balance will be at least $120 million at... More
